Tian-Jiao Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tian-Jiao Zhou has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Hu-Lin Jiang
State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, China
2 shared publications Bi-Te Chen
State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, China
1 shared publication- Chen-Xi Yang
State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China
1 shared publication - Haiping Hao
College of Pharmacy, China Pharmaceutical University
1 shared publication - Han Han
Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China
1 shared publication - Hui Wang
Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China
1 shared publication
Latest Publications
- 21 December 2023
- Published by Elsevier in Journal of Controlled Release
- Vol. 365, 981-1003
Engineered stem cell-based strategy: A new paradigm of next-generation stem cell product in regenerative medicine
- 21 December 2023
- Published by Elsevier in Journal of Controlled Release
- Vol. 365, 981-1003
Engineered stem cell-based strategy: A new paradigm of next-generation stem cell product in regenerative medicine
- Open Access
- 29 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (22) , eaba3167
Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis
This study presents the cell-mediated drug-loaded nanoparticle strategy for selective drugs delivery to treat lung fibrosis.
- 29 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (22) , eaba3167
Open AccessMonocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis
This study presents the cell-mediated drug-loaded nanoparticle strategy for selective drugs delivery to treat lung fibrosis.